Allergies News and Research

Latest Allergies News and Research

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.

19 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

Study findings could lead to new potential drug targets for allergic diseases

Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.

19 Feb 2015

NIAID expands Tuberculosis Research Units program to drive innovation in TB research

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is expanding its Tuberculosis Research Units program in an effort to drive innovation in tuberculosis (TB) research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.

19 Feb 2015

Weill Cornell receives NIH grant to study TB-causing bacteria

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance with voluntary pharmaceutical partners.

19 Feb 2015

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies.

19 Feb 2015

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand--the first study to demonstrate that a vaccine can protect people from HIV infection.

19 Feb 2015

Findings show how human bodies restrict production of IgE to prevent allergic reaction

Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.

16 Feb 2015

Study: Ebola transmission from deceased patients may be possible

To determine how long Ebola virus could remain infectious in a body after death, National Institutes of Health scientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days. They also detected non-infectious viral RNA for up to 70 days post-mortem. The study, published in Emerging Infectious Diseases, suggests that Ebola transmission from deceased individuals may be possible for an extended period of time following death, underscoring the importance of using safe practices for handling corpses.

15 Feb 2015

Diabetes medication can help white blood cells fight bacterial infections

Pioglitazone, a medication approved for treatment of type 2 diabetes, can help bypass genetic defects in chronic granulomatous disease to help white blood cells fight bacterial infections, according to researchers at National Jewish Health.

12 Feb 2015

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients’ health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

Bayer offers wide range of material solutions for OEMs' medical application needs

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients' health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

University of Tokyo researchers reveal how TLR9 binds to pathogen DNA

University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.

10 Feb 2015

Psychedelic drug prevents allergic asthma in mouse model

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.

10 Feb 2015

Discovery improves understanding of factors that trigger allergic asthma

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies.

9 Feb 2015

Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Its name is daunting. It's the hottest topic among allergy experts. It's showing up more and doctors don't yet know why. Allergy specialists at The Ohio State University Wexner Medical Center are seeing more people with eosinophilic esophagitis (EoE), an inflammatory response in the esophagus that makes it hard to swallow food.

9 Feb 2015

Researchers use pulsed light to modify lactose protein that causes 10% of milk-related allergies

The researchers have managed to modify a type of lactose protein called β-lactoglobulin artificially by means of a treatment with pulsed light. This protein, which is present in lactose serum, is responsible for approximately 10% of milk-related allergies. As a result of this treatment, milk becomes much more digestible.

4 Feb 2015

Important tips to prevent food allergies

Food allergies affect over 1.4 million Canadians, and this number is increasing. Allergic reactions to a food can happen quickly and without warning.

4 Feb 2015

Allergies News and Research

Latest Allergies News and Research

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Study findings could lead to new potential drug targets for allergic diseases

NIAID expands Tuberculosis Research Units program to drive innovation in TB research

Weill Cornell receives NIH grant to study TB-causing bacteria

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

Findings show how human bodies restrict production of IgE to prevent allergic reaction

Study: Ebola transmission from deceased patients may be possible

Diabetes medication can help white blood cells fight bacterial infections

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Bayer offers wide range of material solutions for OEMs' medical application needs

University of Tokyo researchers reveal how TLR9 binds to pathogen DNA

Psychedelic drug prevents allergic asthma in mouse model

Discovery improves understanding of factors that trigger allergic asthma

Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Researchers use pulsed light to modify lactose protein that causes 10% of milk-related allergies

Important tips to prevent food allergies

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Allergies News and Research

Latest Allergies News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in